HighTower Advisors Trims Stake in DexCom Medical Device Company

Hedge fund reduces holdings in glucose monitoring firm by over 88% in Q3

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

HighTower Advisors LLC, a major investment management firm, has significantly reduced its stake in DexCom, Inc., a leading medical device company that develops continuous glucose monitoring (CGM) systems for people with diabetes. According to a regulatory filing, HighTower trimmed its holdings in DexCom by 88.3% in the third quarter, selling 401,822 shares and retaining just 53,446 shares worth $3.6 million.

Why it matters

DexCom's CGM technology has become an increasingly important tool for diabetes management, helping patients and clinicians better monitor glucose levels and improve insulin dosing. HighTower's decision to substantially reduce its position in the company could signal a shift in investor sentiment or portfolio strategy, though the reasons behind the move are not entirely clear.

The details

In its latest 13F filing with the SEC, HighTower Advisors reported owning 53,446 shares of DexCom as of the end of the third quarter, down from 455,268 shares held at the end of the prior quarter. This represents an 88.3% reduction in the firm's DexCom holdings during the period. DexCom's stock price has fluctuated in recent months, trading between $54 and $91 over the past year.

  • HighTower Advisors reduced its DexCom stake in the third quarter of 2026.
  • The firm's 13F filing detailing the stake reduction was published on February 26, 2026.

The players

HighTower Advisors LLC

A major investment management firm that has significantly reduced its stake in medical device company DexCom, Inc.

DexCom, Inc.

A leading medical device company that develops continuous glucose monitoring (CGM) systems for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

HighTower's decision to trim its DexCom holdings by over 88% suggests a potential shift in investor sentiment around the medical device company, though the specific reasons behind the move remain unclear. DexCom's CGM technology has become an increasingly important tool for diabetes management, and the company's stock price has fluctuated in recent months.